Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results

Reset filter

Keywords

COVID-19 ×

Show more Keywords

Select data models

Selected data models

You must log in to select data models for download or further analysis.

40 Search results.

Virus finder - F.1

- 6/24/22 - 1 form, 5 itemgroups, 57 items, 3 languages

Itemgroups: Screening Tool,Symptoms,Optional Questions,Data use for future research,Informed Consent

Mischung Beispielfragebogen von Virusfinder und Screening-Tool-Vorschläge von COMPASS vom 22 Okt. 2020, vs3.1 https://www.virus-finder.de Research study of Heidelberg University Hospital and Heidelberg University New Corona testing strategies for the general public Die Studie wurde von einem Team der Universität Heidelberg im Rahmen des bundesweiten Forschungsnetzes zur angewandten Surveillance und Testung durchgeführt, das wiederum zum Nationalen Forschungsnetzwerk der Universitätsmedizin zu Covid-19 gehört. Sie wurden von den örtlichen Gesundheitsämtern unterstützt und vom Bundesministerium für Bildung und Forschung finanziert. "Das neuartige Coronavirus, wissenschaftlich SARS-CoV-2 genannt, stellt uns alle vor große Herausforderungen und wir mussten uns alle in den letzten Monaten wegen der Pandemie stark einschränken. Aktuell wird auf steigende Fallzahlen in der Regel mit einer Verschärfung der Maßnahmen reagiert. Das liegt vor allem daran, dass auch viele Personen ohne Symptome das Virus unerkannt weitertragen und damit nicht rechtzeitig lokal begrenzt reagiert werden kann. Dafür bräuchte es eine Strategie, die frühzeitig auch infizierte Personen ohne Symptome erkennen kann. Mit der Corona-Forschungsstudie erproben wir neue Verfahren hierzu. Im Zeitraum vom 18. November bis 08. Dezember [2020] werden ca. 28.000 Einwohner im Rhein-Neckar-Raum von uns ein Einladungsschreiben zur Teilnahme der Studie erhalten. Die Einladungen werden dabei gleichmäßig verteilt über die Tage verschickt. Sollten Sie in diesem Zeitraum kein Einladungsschreiben erhalten, können Sie leider nicht an der Studie teilnehmen und wir bitten Sie, von Anfragen rund um eine mögliche Teilnahme an der Studie abzusehen. Die Probandinnen und Probanden, d. h. die Menschen, die an der Corona-Forschungsstudie teilnehmen können, wurden dafür zufällig aus den Einwohnermeldeämtern der Gemeinden im Rhein-Neckar-Raum ausgewählt. Solche sogenannten Einwohnermeldestichproben sind nach §46 des Bundesmeldegesetzes zulässig, falls die Studie im öffentlichen Interesse stattfindet." Vielen Dank an Dr. Andreas Deckert für die Erlaubnis zum Upload.

COVID-19

GECCO - German Corona Consensus - Covid-19 Research-Dataset - Laborwerte

- 9/15/21 - 13 forms, 26 itemgroups, 78 items, 1 language

Itemgroups: Datum der Laborwerte,CRP,Ferritin,Bilirubin,D-Dimer,Gamma-GT,GOT/AST,LDH,Kardiale Troponine,Hämoglobin,Kreatinin,Laktat,Leukozyten absolut,Lymphozyten absolut,Neutrophile absolut,PTT (Partielle Thromboplastinzeit/Partial Thromboplastin Time),Thrombozyten absolut,INR (International Normalized Ratio),Serum-Albumin,Antithrombin III,Procalcitonin,Interleukin-6,N-terminales B-Typ natriuretisches Peptid,Fibrinogen,SARS-CoV-2-RT-PCR,SARS-CoV-2-Antikörper-Panel

Disclaimer: Der „GECCO - German Corona Consensus - Covid-19 Research-Dataset“ Inhalt, der auf dem Portal für medizinische Datenmodelle (MDM Portal) zu finden ist, ersetzt nicht den GECCO Datensatz auf simplifier.net. Für die Nutzung von GECCO-FHIR-Profilen verwenden Sie bitte die auf https://simplifier.net/ForschungsnetzCovid-19/ verfügbaren Profile. Der FHIR-Download auf MDM erzeugt lediglich eine FHIR-Fragebogenresource. Ziel Überarbeitung August 2021: höhere Kompatibilität mit der NUM-COMPASS-App bzw. der Schnittstelle zur zentralen Datenbank; Zwischenstand, gewisse Module sind noch nicht kompatibel mit der Schnittstelle (u.a. Medikation und Laborwerte; Beatmungstherapie ist aktuell doppelt hinterlegt) This version of the GECCO logical model is based on https://art-decor.org/art-decor/decor-datasets--covid19f-, and the implementation for REDCap by the University of Tübingen (3.3.2021), partially updated with https://simplifier.net/guide/GermanCoronaConsensusDataSet-ImplementationGuide/Home information. For actual use of FHIR profiles, please use the actual profiles available on https://simplifier.net/ForschungsnetzCovid-19/ResearchDatasetGECCO/~overview (FHIR download on MDM is only a FHIR questionnaire resource). This version is not compatible with the REDCap to FHIR GECCO converter of the University of Tübingen. It aims at a higher compatibility with the app generated for the NUM-COMPASS project (conversion to COMPASS-compatible FHIR questionnaire necessary) and from there with the central platform of the NUM-CODEX project. A few modules are not yet compatible (e.g. Medication and lab values; ventilation is currently double). Official German text from http://cocos.team/datasets.html: Zur Bewältigung der aktuellen Pandemie und der damit einhergehenden Behandlung von Patienten fördert das Bundesministerium für Bildung und Forschung (BMBF) ein nationales Netzwerk der Universitätsmedizin im Kampf gegen COVID-19. Unter anderem soll das Netzwerk die Daten der behandelten COVID-19 Patienten systematisch erfassen und bündeln. Die Forschenden sollen die Behandlung der COVID-19-Patienten standardisiert erheben, verfolgen und analysieren. Die hohe Bedrohungslage hat zu intensiver wissenschaftlicher Aktivität zu COVID-19 geführt, wozu zahlreiche regionale, nationale und internationale epidemiologische Erhebungen und Registerstudien zählen. Der Konsensusdatensatz gibt der Wissenschaft um COVID-19 eine gemeinsame Sprache und Arbeitsgrundlage. Inofficial translation: In order to cope with the current pandemic and the associated treatment of patients, the Federal Ministry of Education and Research (BMBF) is funding a national network of university medicine in the fight against COVID-19. Among other things, the network will systematically collect and bundle the data of the treated COVID-19 patients. The researchers are to collect, track and analyze the treatment of COVID-19 patients in a standardized way. The high threat level has led to intensive scientific activity on COVID-19, including numerous regional, national and international epidemiological surveys and register studies. The consensus data set provides a common language and working basis for the science around COVID-19.

Anamnese/Risikofaktoren

16 itemgroups 101 items

Krankheitsbeginn / Aufnahme

1 itemgroup 3 items

Medikation

5 itemgroups 56 items

The CoRonavIruS Health Impact Survey (CRISIS) V0.3 - Adult Self-Report Baseline Form - Adult Selfreport Baseline Form

- 2/6/22 - 1 form, 14 itemgroups, 189 items, 1 language

Itemgroups: Background,Exposure status last two weeks,Life changes last two weeks,Daily behaviors past three month,Emotions/ Worries past three month,Media use past three month,Substance use past three month,Daily behaviors past two weeks,Emotions/ Worries past two weeks,Media use past two weeks,Substance use past two weeks,Supports disrupted,Additional concerns and comments,Comment section - Adult Selfreport Baseline Form

The CRISIS Survey is designed to enable the researchers and care providers to examine the extent and impact of life changes induced by the epidemic on the mental health and behavior of individuals and families across diverse international settings. Our hope is that such data will enable the identification of pre-, peri, and post-COVID19 demographic, social, and clinical predictors of both short- and long-term impairment and distress induced by COVID19 and its sequelae. The CRISIS can be used to track impact of the survey in diverse clinical, population and research settings. It may be even more informative for identifying predictors of impact and service needs from studies that have well characterized information from prior to COVID19. A broad range of behaviors and function are probed in the survey, including daily behaviors, emotional status, media usage, and substance use. The survey is designed to allow for follow-ups on a regular basis, with recommended frequencies of twice monthly or monthly. To facilitate multicultural perspectives, translations in a broad range of languages are available. Investigators: K. Merikangas, M. Milham, A. Stringaris Collaborators: E. Bromet, S. Colcombe, V. Zipunnikov The team encourages advanced notification of any media, scientific reports or publications of data that have been collected with the CRISIS (merikank@mail.nih.gov), though this is not required. We also encourage voluntary data sharing for the purpose of psychometric studies that will be led by Dr. Stringaris (argyris.stringaris@nih.gov).

Risk perception and optimism during the early stages of the COVID-19 pandemic - Questionnaire risk perception and optimism about COVID-19

- 1/5/22 - 1 form, 7 itemgroups, 151 items, 1 language

Itemgroups: Risk perception for COVID-19,Control questions for optimism,Adherence to protective measures,Mental health,General control questions,Other,Demographics

In this study, we assessed risk perception and optimism about COVID-19 in a multinational (UK, USA and Germany), longitudinal design during the early stages of the pandemic (16 March 2020; 1 April 2020; 20 May 2020). Our main findings are that (i) people showed a comparative optimism bias about getting infected and infecting others, but not for getting severe symptoms, (ii) this optimism bias did not change over time, (iii) optimism bias seemed to relate to perceived level of control over the action, (iv) risk perception was linked to publicly available information about the disorder, (v) people reported adhering closely to protective measures but these measures did not seem to be related to risk perception, and (vi) risk perception was related to questions about stress and anxiety. Kuper-Smith BJ, Doppelhofer LM, Oganian Y, Rosenblau G, Korn CW. 2021 Risk perception and optimism during the early stages of the COVID-19 pandemic. R. Soc. Open Sci. 8: 210904. https://doi.org/10.1098/rsos.210904

COVID-Follow-Up - Verlaufsdokumentation

- 11/5/21 - 1 form, 3 itemgroups, 13 items, 12 languages

Itemgroups: Vitalzeichen,Symptome,Medikamente

Follow-Up of COVID-19 positive risk patients to document course of disease

COVID-19 Medical History - Corona Anamnese

- 11/5/21 - 1 form, 5 itemgroups, 25 items, 12 languages

Itemgroups: Symptome,Kontakt,Risikogebiet,Allgemeine Angaben,Ergänzungen

COVID-19 Medical History in 12 languages

COVID-19 Status Form of Rhön-Klinikum Bad Neustadt - Pre-hospital COVID-19-Status Form

- 9/28/21 - 2 forms, 4 itemgroups, 26 items, 1 language

Itemgroups: Exclusion Criteria for inpatient admission,Immune Status COVID-19,Additional Information for risk assessment,Signature

COVID-19 Status forms of the Rhön-Klinikum Campus Bad Neustadt, Germany. * pre-hospital * on admission They are used for the assessment of COVID-19 risk before (via telephone) and on the day of admission. If one of the 4 exclusion criteria is answered with "yes" a physician/clinician has to make the decision about medical requirement for admission. Provided by the Medical Documentation Department of the Rhön-Klinikum Campus Bad Neustadt. German Description: Die Patienten werden zunächst vor dem stationären Aufenthalt angerufen und gefragt, ob sie in Quarantäne sind oder Kontaktpersonen oder vielleicht doch erkrankt. Wurde eine dieser Fragen mit Ja beantwortet, dann muss ein Arzt entscheiden und der Patient wird am Aufnahmetag nur mit medizinischer Notwendigkeit aufgenommen.

COVID-19 Status on admission day

3 itemgroups 14 items

ISARIC/WHO Novel Coronavirus (nCoV) / COVID-19 Case Record Form - MODULE 3: OUTCOME CASE REPORT FORM

- 9/20/21 - 1 form, 12 itemgroups, 138 items, 1 language

Itemgroups: Participant Identification,Treatment,Complications,Diagnostics,Biospecimen Testing,Antiviral therapy,Antibiotic therapy,Corticosteroids,Heparin,Antifungal therapy,Other treatments administered for COVID-19,Outcome

This CRF is set up in modules to be used for recording data on the ISARIC COVID-19 Core Database or for independent studies. Module 1 and Module 2 complete on the first day of presentation/admission or on first day of COVID-19 assessment. Module 2 also complete on first day of admission to ICU or high dependency unit. In addition, complete daily for as many days as resources allow up to a maximum of 14 days. Continue to follow-up patients who transfer between wards. Module 3 (Outcome) complete at discharge or death General Guidance: - The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected retrospectively if the patient is enrolled after the admission date. - For more detailed guidance on how to complete these forms, please refer to the CRF Completion Guideline - Participant Identification Numbers consist of a 3 digit site code and a 4 digit participant number. You can obtain a site code and registering on the data management system by contacting ISARIC. Participant numbers should be assigned sequentially for each site beginning with 0001. In the case of a single site recruiting participants on different wards, or where it is otherwise difficult to assign sequential numbers, it is acceptable to assign numbers in blocks or incorporating alpha characters. E.g. Ward X will assign numbers from 0001 or A001 onwards and Ward Y will assign numbers from 5001 or B001 onwards. Enter the Participant Identification Number at the top of every page. - Printed paper CRFs may be used for later transfer of the data onto the electronic database. - For participants who return for re-admission to the same site, start a new form with a different Participant Identification Number. Please check “YES-admitted previously” in the ONSET & ADMISSION section. Enter as 2 separate entries in the electronic database. - For participants who transfer between two sites that are both collecting data on this form, it is preferred to have the data entered by a single site as a single admission, under the same Participant Identification Number. When this is not possible, the first site should record “Transfer to other facility” as an OUTCOME, and the second site should start a new form with a new patient number and indicate “YES-transferred” in ONSET & ADMISSION. - Complete every line of every section, except for where the instructions say to skip a section based on certain responses. - Mark ‘Not done’ for any results of laboratory values that are not available, not applicable or unknown. - Avoid recording data outside of the dedicated areas. Sections are available for recording additional information. - If using paper CRFs, we recommend writing clearly in ink, using BLOCK-CAPITAL LETTERS. - Place an (X) when you choose the corresponding answer. To make corrections, strike through (-------) the data you wish to delete and write the correct data above it. Please initial and date all corrections. - Please keep all of the sheets for a single participant together e.g. with a staple or participant-unique folder. - ISARIC would like the centers to enter data directly into their electronic data capture system. Please contact ISARIC about access. If your site would like to collect data independently, ISARIC can support you in the estabilishment of locally hosted databases. This version may serve as a basis for locally hosted databases. - Please contact ISARIC, if you need help with databases, have comments or to let ISARIC know that you are using the CRF. - Please let us know if you find any mistakes in the MDM Portal's version. FURTHER GUIDANCE AND DEFINITIONS (from the Completion guideline) Comorbidities: Comorbidities present before the onset of COVID-19 and are still present. Do not include those that developed following the onset of COVID-19 symptoms. More detailed guidance is provided. Hospital admission: For patients who were admitted to hospital with COVID-19 or symptoms consistent with possible COVID-19 infection, please enter details for the date of hospital admission. For patients with a clear alternative diagnosis leading to admission who subsequently acquired COVID-19, original admission date should be provided, but all subsequent references to admission should be taken as referring to day COVID-19 was first clinically suspected (or within the first 24 hours after first day of suspected or confirmed COVID-19 infection). Where a patient was admitted via multiple hospital departments, count admission from the time they came to the first department during the visit that led to their admission (e.g. arrival at the Emergency Department). Oxygen therapy: Include any form of supplemental oxygen received using any methods. Invasive ventilation: Please include any mechanical ventilation delivered following intubation or via a tracheostomy. Do not include patients who are breathing independently via a tracheostomy. Non-invasive ventilation: Please include any positive-pressure treatment given via a tight-fitted mask. This can be continuous positive pressure (CPAP) or bi-level positive pressure (BIPAP). Renal replacement therapy or dialysis: Please include any form of continuous renal replacement therapy or intermittent haemodialysis. Worst result: References to ‘worst result’ refer to those furthest from the normal physiological range or laboratory normal range. Results that were rejected by the clinical team (e.g. pulse oximetry on poorly perfused extremities, haemolysed blood samples, contaminated microbiology results) should not be reported. The following measures should be considered as a single observation and entered together: Blood gas results: Please report the measures from the blood gas with the lowest pH (most acidotic). Blood pressure: Please report the systolic and diastolic blood pressure from the observation with the lowest mean arterial pressure (if mean arterial pressure has not been calculated, report the measurement with lowest systolic blood pressure). Respiratory rate: If both abnormal low and high rate observed, record the abnormally high rate. General information about ISARIC ISARIC has developed a portfolio of resources to accelerate outbreak research and response. All resources are designed to address the most critical public health questions, have undergone extensive review by international clinical experts, and are free to use. ISARIC should be acknowledged and informed if you implement the protocol. Ethical apporval of the protocol and all necessary operational and financial arrangements are the responsibility of the investigators. This form refers to the CoV CASE RECORD FORM Version 1.3 25 Aug 2020. See https://isaric.tghn.org/COVID-19-CRF/

Multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19 - MODULE 2: OUTCOME CASE REPORT FORM

- 8/11/21 - 1 form, 7 itemgroups, 195 items, 1 language

Itemgroups: Participant Identification,Summary of clinical features of current illness,Laboratory results,Imaging and pathogen testing,Treatment,Supportive care,Outcome

Preliminary case definition Children and adolescents 0–19 years of age with measured or self-reported fever ≥ 3 days AND two or more of the following: a) Rash or bilateral non-purulent conjunctivitis or muco-cutaneous inflammation signs (oral, hands or feet) b) Hypotension or shock c) Features of myocardial dysfunction, or pericarditis, or valvulitis, or coronary abnormalities (clinical features, ECHO findings, or laboratory markers such as elevated Troponin/NT-proBNP) d) Evidence of coagulopathy (such as abnormal PT, PTT, elevated d-Dimers) e) Acute gastrointestinal problems (such as diarrhoea, vomiting or abdominal pain) AND Elevated markers of inflammation such as ESR, C-reactive protein or procalcitonin AND No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes AND Evidence of current or previous COVID-19 (RT-PCR, antigen test or serology positive) or likely contact with patients with COVID NB Consider this syndrome in children with features of typical or atypical Kawasaki disease or toxic shock syndrome. Based on CRF on https://isaric.org/research/covid-19-clinical-research-resources/multisystem-inflammatory-syndrome-mis-c/ This Case Report Form (CRF) has been developed by ISARIC in cooperation with WHO's working group (https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19) to use as a standalone CRF for children and adolescents presenting with syndrome of suspected Multisystem Inflammatory Syndrome (MIS-C). This Module is to be completed at time of discharge or death.

Multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19 - MODULE 1: PRESENTATION/ADMISSION CASE REPORT FORM

- 8/3/21 - 1 form, 10 itemgroups, 188 items, 1 language

Itemgroups: Participant Identification,Demographics,Onset of current illness and vital signs,Possible signs and symptoms of multisystem inflammatory syndrome,Other signs and symptoms of multisystem inflammatory syndrome,Recent history,Co-morbidities, past history,Pre-admission and chronic medication,Laboratory results,Imaging and pathogen testing

Based on CRF on https://isaric.org/research/covid-19-clinical-research-resources/multisystem-inflammatory-syndrome-mis-c/ This Case Report Form (CRF) has been developed by ISARIC in cooperation with WHO's working group (https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19) to use as a standalone CRF for children and adolescents presenting with syndrome of suspected Multisystem Inflammatory Syndrome (MIS-C). Preliminary case definition Children and adolescents 0–19 years of age with measured or self-reported fever ≥ 3 days AND two or more of the following: a) Rash or bilateral non-purulent conjunctivitis or muco-cutaneous inflammation signs (oral, hands or feet) b) Hypotension or shock c) Features of myocardial dysfunction, or pericarditis, or valvulitis, or coronary abnormalities (clinical features, ECHO findings, or laboratory markers such as elevated Troponin/NT-proBNP) d) Evidence of coagulopathy (such as abnormal PT, PTT, elevated d-Dimers) e) Acute gastrointestinal problems (such as diarrhoea, vomiting or abdominal pain) AND Elevated markers of inflammation such as ESR, C-reactive protein or procalcitonin AND No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes AND Evidence of current or previous COVID-19 (RT-PCR, antigen test or serology positive) or likely contact with patients with COVID NB Consider this syndrome in children with features of typical or atypical Kawasaki disease or toxic shock syndrome. This Module is to be completed when multisystem inflammatory syndrome is suspected, on admission or in-patients.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Baseline I

- 7/16/21 - 23 forms, 39 itemgroups, 280 items, 1 language

Itemgroups: Sociodemography,Comorbidities, Central nervous system / Neurological disesases,Comorbidities, Cardiovascular diseases,Comorbidities, Pulmonary diseases,Comorbidities, Hematological / oncological diseases,Comorbidities, Rheumatological diseases,Comorbidities, Allergology,Comorbidities, Other internal disorders,Comorbidities, Other conditions,Body-Mass-Index (BMI),Smoking status,Use of e-cigarettes and / or vaporizer?,Pre-existing treatment,Recent immunosuppressive medication,Colonisation with multi-resistant pathogens,Disease limiting life expectancy before positive SARS-CoV-2 testing,Follow-up duration after SARS-CoV-2 diagnosis,Last known status,Diagnosis context,COVID-19 diagnosis details,Complications at baseline: Thrombotic and thromboembolic manifestations,Complications at baseline: Neurological,Complications at baseline: Other severe organ damage,Complications at baseline: Other,Disease course,Duration (days) of...,Symptoms: Please click all symptoms which occurred in the respective clinical phase,Vitals,Lung ultrasound results at SARS-CoV-2 detection,Baseline: Chest CT results at SARS-CoV-2 detection,Heart function, Echocardiography: Ejection fraction (EF) at SARS-CoV-2 detection,Cardiovascular magnetic resonance imaging (CMR) performed in any clinical phase,Neurological diagnostic in various phases,Complementary and/or integrative medicine (CIM) used in any phase,Discussion of limitation of therapy during SARS-CoV-2 infection,Specialist palliative care during SARS-CoV-2 infection,Agreement to share data for scientific purposes,Biomaterial availability for research proposes,Participation in interventional clinical trials

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. Please note that only cases with known outcome are collected! Baseline / diagnosis is defined as the day the sample of the first positive SARS-CoV-2 result was taken. Criteria of the Uncomplicated Phase: Asymptomatic OR Symptoms of upper respiratory tract infection and/or Nausea, emesis, diarrhea and/or Fever Remember: The Uncomplicated Phase ends, if a previously febrile patient has no fever anymore and has completed 14 days of follow-up without entering Complicated or Critical Phase; then move to Recovery Phase. Also, as soon as one of the criteria of the Complicated or Critical Phase are fulfilled, Uncomplicated Phase ends; move over to there. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Complicated Phase: * Need for oxygen supplementation (In patients with prior oxygen home therapy, clinically meaningful increase in need for oxygenation.) * paO2 at room air < 70 mmHg * SO2 at room air < 90 % * GOT or GPT > 5x ULN * New cardiac arrhythmia * New pericardial effusion >1cm * New heart failure with pulmonary edema, congestive hepatopathy or peripheral edema Remember: The Complicated Phase ends, if none of the criteria for the Complicated Phase is fulfilled anymore AND the patient is free of fever; then move to Recovery Phase. Also, as soon as one of the criteria of the Critical Phase are fulfilled, Complicated Phase ends; move over to Critical Phase. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Critical Phase: * Need for catecholamines * Life-threatening cardiac arrhythmia * Mechanical ventilation (invasive or non-invasive) * Liver failure with Quick< 50% * qSOFA >= 2 * Renal failure in need of dialysis Remember: The Critical Phase ends as soon as none of the criteria for the Critical Phase is fulfilled anymore AND the patient is free of fever. If the patient has died, it ends with the death of the patient. If the patient has died, do not report terminal values, i.e. those recorded after turning off life-support or heart rate "0" after death of the patient. Criteria of the Recovery Phase: *Improvement by at least one phase, i.e. Critical to Complicated or Complicated to Uncomplicated * Defervescence Remember: Uncomplicated asymptomatic patients enter recovery phase after 14 days of observation without disease progression No further progression or re-hospitalization If a text field can't be filled out, note 'ND' (for not determined).

Diagnostics (General virological and laboratory findings for all phases)

46 itemgroups 320 items

Immunosuppressive premedication

31 itemgroups 90 items

HIV sub-cohort

13 itemgroups 55 items

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Pulmonary sub-cohort

- 7/1/21 - 1 form, 6 itemgroups, 30 items, 1 language

Itemgroups: Chronic pulmonary disease other than asthma and copd,Oxygen ventilation/ oxygen support before SARS-CoV-2 detection,Regular use of inhaler,Prior pulmonary function (Spirometrie) before COVID-19,Pulmonary function (Spirometrie) at diagnosis of COVID-19,Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 21.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for the pulmonary sub-cohort. If a text field can't be filled out, note 'ND'.

Keywords

Table of contents

Selected data models

40 Search results.

Contact

Help